Pentosan Polysulfate Sodium and Maculopathy in Patients with Interstitial Cystitis: A Systematic Review and Meta-Analysis

被引:0
|
作者
Lee, Jongsoo [1 ]
Kim, Yun Jin [2 ]
Lee, Konghee [3 ]
Kim, Young Kook [4 ,5 ]
Rhee, Taeho Greg [6 ,7 ]
Shim, Sung Ryul [8 ,9 ,10 ]
Kim, Jae Heon [11 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Dept Urol, Seoul, South Korea
[2] Soonchunhyang Univ, Bucheon Hosp, Dept Pathol, Bucheon 14584, South Korea
[3] Zenit Urol Clin, Chang Won, South Korea
[4] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea
[5] EyeLight Data Sci Lab, Seoul, South Korea
[6] Yale Sch Med, Dept Psychiat, New Haven, CT USA
[7] Univ Connecticut, Sch Med, Dept Publ Hlth Sci, Farmington, CT USA
[8] Konyang Univ, Coll Med, Dept Biomed Informat, 158 Gwanjeodong Ro, Daejeon 35365, South Korea
[9] Konyang Univ Hosp, Konyang Med Data Res Grp KYMERA, Daejeon 35365, South Korea
[10] Konyang Univ Hosp, Myunggok Med Res Ctr, Daejeon, South Korea
[11] Soonchunhyang Univ, Coll Med, Dept Urol, Seoul Hosp, 59 Daesagwan Ro, Seoul 04401, South Korea
关键词
Cystitis; interstitial; Drug-related side effects and adverse reactions; Macular degeneration; Pentosan sulfuric polyes- ter; Retinal diseases; PREVALENCE; SYMPTOMS;
D O I
10.5534/wjmh.240295
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Purpose: Pentosan polysulfate sodium (PPS) is the only pharmacological intervention approved by the US Food and Drug Administration for treating interstitial cystitis (IC) to date. However, PPS may induce an adverse event, maculopathy, which can be a significant challenge. To determine the risk of PPS-induced maculopathy in patients with IC. Materials and Methods: PubMed and Embase were systematically searched through July 2024. Two authors also independently and manually searched all relevant studies. We included national level cohort studies using healthcare claim big data or real-world data with the following criteria: (1) patients diagnosed with IC; (2) interventions included PPS as an active treatment; (3) comparisons were specified as non-PPS interventions; and (4) the primary outcome of interest was the risk of maculopathy. The pairwise meta-analysis was performed to compare the PPS treatment group with control used in IC. The primary outcome measure was the hazard ratio (HR), odds ratio (OR), and proportional report ratio (PRR) of maculopathy after receiving the PPS treatment, as compared to non-PPS interventions. Results: A comprehensive literature search was conducted, and identified 6 studies with 411,098 patients. The pooled risk for maculopathy due to PPS in patients with IC was significant (HR, 1.678; 95% confidence interval [95% CI], 1.066-2.642]). The heterogeneity test produced a Higgins' I-squared statistic, which was 83.6%. In the subgroup analysis of follow-up period of less than 5 years (HR, 1.285; 95% CI, 1.139-1.449) and more (HR, 1.341; 95% CI, 1.307-1.375) were statistically significant, indicating that the patients with IC who had a long-term PPS treatment were more likely to have maculopathy than the control groups. Conclusions: This is the first study to investigate the relationship between PPS and its association with the risk of maculopathy in patients with IC through a systematic review and meta-analysis.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] PATIENT PERCEPTION OF OCULAR RISK IN PENTOSAN POLYSULFATE USE FOR INTERSTITIAL CYSTITIS
    Kaefer, Daniela
    Lee, Victoria
    Limbrick, Bree'ava
    Sarraf, David
    Kim, Ja-Hong
    JOURNAL OF UROLOGY, 2021, 206 : E34 - E34
  • [32] Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis
    Nickel, JC
    Barkin, J
    Forrest, J
    Mosbaugh, PG
    Hernandez-Graulau, J
    Kaufman, D
    Lloyd, K
    Evans, RJ
    Parsons, CL
    Atkinson, LE
    UROLOGY, 2005, 65 (04) : 654 - 658
  • [33] Sentiments of Individuals with Interstitial Cystitis/Bladder Pain Syndrome Toward Pentosan Polysulfate Sodium: Infodemiology Study
    Hswen, Yulin
    Qin, Qiuyuan
    Smith, Pressley
    Swierczynski, Alison
    Bauer, Stuart
    Ladson, Erika
    Garrett, Amanda Leigh
    Brownstein, Catherine A.
    JMIR FORMATIVE RESEARCH, 2025, 9
  • [34] Pentosan polysulfate sodium maculopathy: Final analysis of a prospective cohort, updated review, and association with inflammatory bowel disease
    Santina, Ahmad
    Feo, Alessandro
    Bousquet, Elodie
    Velaga, Swetha B.
    Abraham, Neda
    Fogel-Levin, Meira
    Romero-Morales, Veronica
    Somisetty, Swathi
    Wong, Alice
    Lu, Anthony
    Nittala, Muneeswar
    Chhablani, Jay
    Voichanski, Shilo
    Au, Adrian
    Sadda, Srinivas
    Sarraf, David
    SURVEY OF OPHTHALMOLOGY, 2025, 70 (03) : 583 - 592
  • [35] Association between a newly described pigmentary maculopathy and pentosan polysulfate sodium
    Shah, Rachel
    Hanif, Adam Marcus
    Yan, Jiong
    Cribbs, Blaine
    O'Keefe, Ghazala
    Yeh, Steven
    Hendrick, Andrew
    Shantha, Jessica
    Hubbard, G. Baker
    Patel, Purnima
    Rao, Prethy
    Jain, Nieraj
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [36] Association and prevalence of pentosan polysulfate sodium use with drug related maculopathy
    Arias, Juan
    Kalaw, Fritz Gerald Paguiligan
    Walker, Evan
    Borooah, Shyamanga
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [37] A protocol of systematic review and meta-analysis of neuromuscular electrical stimulation for interstitial cystitis
    Chen, Da-yin
    Guo, Ying-xue
    Dong, Long-xin
    He, Wen-jie
    Cao, Hui-feng
    Wang, Ping
    Yue, Cai-fang
    MEDICINE, 2020, 99 (28) : E21088
  • [38] Quality of life in patients with interstitial cystitis/painful bladder syndrome after treatment with DMSO, BCG, cyclosporine and pentosan polysulfate sodium
    Sairanen, J.
    Leppilahti, M.
    Tammela, T.
    Ruutu, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 169 - 169
  • [39] Retrospective study of incidence/prevalence of pigmentary maculopathy and retinopathy in patients receiving pentosan polysulfate sodium
    Yuan, Zhong
    Vaughan, Subusola
    Jeffcoat, Carolyn
    Hu, Peter
    Yuson, Ritchie
    Fife, Daniel
    Borkar, Durga
    PLOS ONE, 2025, 20 (01):
  • [40] Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation
    Shah, Rachel
    Simonett, Joseph M.
    Lyons, Riley J.
    Rao, Rajesh C.
    Pennesi, Mark E.
    Jain, Nieraj
    JAMA OPHTHALMOLOGY, 2020, 138 (08) : 894 - 900